| Sarcoidosis versus controls | Resolved versus controls | Persistent versus controls | Resolved versus persistent | |||||||||
| % | p-value | OR (95% CI) | % | p-value | OR (95% CI) | % | p-value | OR (95% CI) | % | p-value | OR (95% CI) | |
| Influence of independent MHC markers on disease susceptibility¶ | ||||||||||||
| DRB1*03:01 pos# | 0.002 | 2.8 (1.47–5.22) | 0.005 | 2.8 (1.37–5.50) | ||||||||
| DRB1*15:01 pos# | 0.036 | 1.7 (1.03–2.63) | 0.001 | 2.7 (1.49–4.93) | ||||||||
| DPB1*04:02 neg | 0.007 | 2.0 (1.20–3.17) | 0.004 | 2.4 (1.32–4.39) | ||||||||
| DRB1*04:01-DPB1*04:01 pos | 0.006 | 3.4 (1.42–8.24) | 0.027 | 3.1 (1.14–8.65) | ||||||||
| Influence of marker combinations on disease susceptibility+ | ||||||||||||
| DPB1*04:02 neg, rs2076530 (A) pos | 72 versus 53 | <0.001 | 2.3 (1.44–3.57) | 79 versus 53 | <0.001 | 3.2 (1.80–5.73) | 65 versus 79 | 0.041 | 0.5 (0.27–0.98) | |||
| DRB1*01:01 neg, rs2076530 (A) pos | 82 versus 70 | 0.008 | 2.0 (1.20–3.34) | 87 versus 70 | 0.002 | 2.8 (1.42–5.33) | ||||||
| DPB1*04:02 neg, DRB1*01:01 neg | 72 versus 52 | <0.001 | 2.3 (1.49–3.66) | 69 versus 52 | 0.012 | 2.0 (1.16–3.49) | 75 versus 52 | <0.001 | 2.7 (1.55–4.70) | |||
| DRB1*01:01 neg, DPB1*04:02 neg, rs2076530 (A) pos | 68 versus 49 | <0.001 | 2.2 (1.43–3.48) | 74 versus 49 | <0.001 | 2.9 (1.68–5.07) | ||||||
Sarcoidosis n = 187, resolved sarcoidosis n = 89, persistent sarcoidosis n = 98, controls n = 150. One patient with resolved sarcoidosis failed the rs2076530 genotyping and was excluded from the analyses. A value of p<0.05 is considered statistically significant. The p-values are uncorrected. The positivity (pos) of a carrier of a specific variant (or variants) was considered when the subject had one or two copies of the variant. Neg: negativity or absence of the variant. #: significant association with sarcoidosis in our previous study: HLA-DRB1*01:01, *03:01 and *15:01 [8]. ¶: the logistic regression model (stepwise forward) was used for studying the relationship between the significantly associated markers and the disease, to estimate the effects of individual markers. +: Chi-squared analysis.